Abstract
Keloids are characterized by excessive collagen deposition and persistent inflammation, causing high morbidity and recurrence with limited effective treatments. In this study, MIL‐100(Fe)– a metal‐organic framework composed of ferrous/ferric ion nodes and 1,3,5‐benzenetricarboxylate ligands– is synthesized via a microwave‐assisted hydrothermal method and demonstrated nanoscale particle size (141.7 nm). In vitro, human keloid fibroblasts maintained >90% viability after 48 h with MIL‐100(Fe) treatment and showed robust cellular uptake within 2 h, compared to PBS‐treated controls. MIL‐100(Fe) significantly reduced fibroblast migration and downregulated fibrosis‐associated proteins after 48 h, including collagen I, collagen III, transforming growth factor beta 1 (TGF‐β1), SMAD3, and prolyl 4‐hydroxylase subunit alpha 1 (P4HA1). Western blot analysis confirmed that TGF‐β1 expression is more strongly suppressed in human keloid fibroblasts than in human monocytes. In an in vivo humanized keloid mouse model, four weeks of intralesional MIL‐100(Fe) injection reduced fibrous tissue volume by 27% by week two post‐treatment compared with controls. Histological analysis showed decreased fibroblast density, decreased collagen fiber area, polarized macrophage infiltration, and vacuolization in the MIL‐100(Fe) treated group. These findings suggest that MIL‐100(Fe) selectively targets the TGF‐β/SMAD pathway, thereby reducing collagen deposition and fibrosis, and highlight its potential as a therapeutic nanoplatform for keloid treatment.
Funding Information
  • National Science and Technology Council (110‐2314‐B‐182 ‐048 ‐MY3)
  • National Science and Technology Council (111‐2124‐M‐002‐021)
  • National Science and Technology Council (111‐2628‐E‐002‐008)
  • Chang Gung Memorial Hospital, Linkou (CMRPG3M0291‐3)
  • Ministry of Education (113L9008)

This publication has 58 references indexed in Scilit: